Oncology
Page 3 • 12 itemsGlobal oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
EMA Issues Positive Opinion for Viatris' Palbociclib Generic Cancer Treatment
European Medicines Agency issues positive opinion for Viatris' generic palbociclib, potentially expanding access to this important breast cancer treatment.
CAR-T Access EU Policy: Impact of Cross-Border Healthcare on Advanced Therapies
This article examines the implications of cross-border healthcare policies on CAR-T therapies for cancer, highlighting access challenges and opportunities in the EU.
RenovoRx TAMP Therapy Platform Data Accepted for 2026 ASCO Presentation - Phase III TIGeR-PaC Trial Results
RenovoRx announces ASCO acceptance of pharmacokinetic data from Phase III TIGeR-PaC trial testing TAMP therapy platform for pancreatic cancer treatment.
EU Orphan Drug Designation: Successes & Market Access in Rare Cancers
This article delves into the EU Orphan Drug Designation process, showcasing successes and market access strategies for rare cancer treatments like XYZ.
Treatment Sequencing in NSCLC: Insights from EU Guidelines and ESMO
This article delves into the latest EU guidelines and ESMO recommendations on treatment sequencing for non-small cell lung cancer (NSCLC), highlighting osimertinib's role.
EMA Cell Therapy Framework: Impact on CAR-T Availability in Europe
The EMA Cell Therapy Framework aims to enhance CAR-T therapy access in Europe, potentially transforming treatment options for hematological malignancies.
Center for Cancer and Blood Disorders Launches CAR T-Cell Therapy Program in Maryland, Expanding Community Access
CCBD becomes first Maryland community oncology practice to offer FDA-approved CAR T-cell therapy, significantly expanding patient access in the region.
Repertoire Immune Medicines Doses First Patient in RPTR-1-201 Phase 1/2 Trial for Advanced Solid Tumors
Repertoire Immune Medicines begins Phase 1/2 trial of RPTR-1-201, a novel TCR bispecific therapy targeting advanced solid tumors across US and European sites.
Alpha Tau Treats First Patient with Alpha DaRT in European Pancreatic Cancer Trial ACAPELLA
Alpha Tau initiates Alpha DaRT treatment in ACAPELLA trial for locally advanced pancreatic cancer, addressing unmet need for 42,000 European patients annually.
Alpha Tau Treats First European Pancreatic Cancer Patient with Alpha DaRT in ACAPELLA Clinical Trial
Alpha Tau successfully treats first European patient with Alpha DaRT radiotherapy in French ACAPELLA trial for locally advanced pancreatic cancer.
Blinatumomab Long-Term Safety Study in Pediatric Leukemia Patients Reaches Final Stage
European study evaluating long-term safety of blinatumomab versus chemotherapy in pediatric acute lymphoblastic leukemia patients nears completion.
Pembrolizumab Plus Lenvatinib Shows Promise for Rare Clear Cell Gynecological Cancers in Phase 2 Trial
LARA Phase 2 trial published in The Lancet Oncology demonstrates promising clinical activity of pembrolizumab plus lenvatinib for recurrent clear cell cancers.